CClinicalTrials.gg
CompletedNCT05087927IFE4PrEPUpdated Sep 20, 2024

Study for IFE4PrEP Intervention on PrEP Uptake by Southern African American Women

An observational study in HIV Prevention, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-20.

Sponsored by University of North Carolina, Chapel Hill · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
31
Ages
18 Years and older
Sex
Female
01

Study summary

Purpose: This study is partnering with communities to identify the best ways to provide HIV prevention communication and services for women living in public housing who have been disproportionately affected by HIV but underserved by current HIV prevention programs. The investigators want to work with community members to develop and design the delivery of a program to promote awareness of and access to pre-exposure prophylaxis (PrEP) for HIV prevention among women living in public housing.

Participants: Up to 248 cisgender females who are 18 years of age or older and currently reside in Durham Housing Authority (DHA) housing will be enrolled in this study at UNC.

Procedures (methods): Data collection for this formative study will consist of 4 focus groups of up to 12 women in each focus group living in DHA as well as a survey of 200 women living in DHA.

Read the detailed description

Study Design

This observational formative study consists of cross-sectional data collection with women living in DHA (Durham Housing Authority) housing through surveys and focus group discussions. Both modes of data collection will service to collect descriptive information to refine the intervention. The survey will also include a randomized messaging experiment (see Data Collection Procedures description below).

Study Duration, Enrollment and Number of Subjects

This formative study will last up to one year (12 months). The investigators will enroll up to 248 participants (up to 200 survey participants and up to 48 focus group participants with some women participating in both) as recruitment allows and as necessitated by thematic saturation.

Study Population

The target population for this study is African American cisgender women at least 18 years old residing in DHA community housing. The vast majority of DHA residents are African American, so the investigators anticipate recruiting participants who are majority African American without explicitly excluding prospective participants on the basis of race. Women will be eligible to participate if they meet the following criteria:

  1. 18 years of age or older
  2. Identify as cisgender female (assigned female sex at birth and currently identify as female)
  3. Currently reside in Durham Housing Authority (DHA) housing

Data Collection Procedures

Survey

The self-administered electronic survey will assess the topics listed below and will include a randomized messaging experiment to assess the effect of exposure messaging about PrEP with variable framing on attitudes and perceived norms about PrEP. Participants will complete the survey as follows:

  • Women recruited through community network referral may complete the survey on their own device at the time of their choosing.
  • Women recruited through community/public events or FGDs will be provided the option to either: a) complete the self-administered electronic survey during the event on a study-owned device (if an in-person event). Limited literacy, vision-impaired, or any participant who desires assistance may request that a study staff member read the questions aloud to them for them to complete the survey, or request to complete the survey as an interviewer-administered survey in a private location; or b) complete the survey at a time of their choosing on their own device.

Survey topics will include:

  • Sociodemographic characteristics (age, race/ethnicity, DHA community of residence)
  • PrEP awareness \& knowledge
  • Attitudes toward PrEP
  • Randomized messaging experiment (see below)
  • Perceived PrEP norms
  • Perceived ability to access PrEP
  • Barriers and facilitators to using PrEP
  • Perceived HIV risk
  • HIV risk factors/behaviors
  • Likelihood to use PrEP/interest/willingness to use PrEP
  • Perceived stigmas

The survey will include an embedded randomized 2 x 2 between-subjects experiment (gain vs. loss framing by intrinsic vs. extrinsic motivation messaging) evaluating the effects of the alternative messaging approaches on intermediate endpoints in Table 3 of the protocol to identify the approaches most associated with positive PrEP attitudes and norms. The experiment will be embedded in a questionnaire administered before focus group sessions to 40 focus group participants and to 160 additional women in study communities (total of 200, 50 per community). During each of the 4 focus groups, the investigators also will explore women's reactions to alternative modes (e.g., flyers, posters, apps, social media) of PrEP messaging.

Hypotheses for each messaging attribute are as follows:

H1: Gain framing will be associated with more positive attitudes and more positive perceived norms about PrEP than loss framing.

  • Gain framing: PrEP puts me in control
  • Loss framing: Without PrEP, I'm less in control

H2: Demographic targeting will be associated with more positive attitudes and more positive perceived norms about PrEP than non-demographically targeted messaging.

  • Demographically targeted: [Image of African American woman]
  • Extrinsic framing: [Image of women of multiple races]

Focus Group Discussions (FGDs)

Focus Group participants will be given the option to participate in a focus group by Zoom or in person. Per North Carolina Executive Orders current at the time of data collection, the investigators anticipate that in-person FGDs will be conducted in a private indoor location with sufficient ventilation, 6-foot distancing between participants, and with face masks for both FGD facilitators and participants. Focus groups with limited participants showing up may be converted to individual in-depth interviews. With participant consent, FGDs will be audio-recorded for analysis. Zoom focus groups will be video/audio-recorded with the video deleted and the audio retained directly following the FGD. Focus groups will be led by trained study staff members who will facilitate a discussion on the topics below:

  • Current awareness \& knowledge of PrEP (including current sources of information about PrEP)
  • Attitudes toward PrEP (including any stigmas about PrEP, perceived risk)
  • Perceptions of and recommendations for messaging about PrEP use among cisgender women (open-ended then specific reactions)
  • Perceptions of and recommendations for messaging about PrEP mobile unit (open-ended then specific reactions)
  • Preferences for mobile PrEP unit delivery features (e.g., timing, location, appointment type, delivery of complementary services).
  • Best media/modes for providing messages about PrEP and the mobile unit to women in DHA.
  • Perceptions of peer networkers, best approach for contacting residents and providing information.
  • Barriers and facilitators to using PrEP
02

Conditions studied

  • HIV Prevention

Keywords

  • HIV
  • pre-exposure prophylaxis
  • PrEP
  • Prevention
  • Women's Health
  • Health Messaging
03

In context

Lead sponsor

University of North Carolina, Chapel Hill is the lead sponsor of 1,340 studies on the registry; 133 are open to participants now.

Of its 155 completed or terminated interventional studies of FDA-regulated products, 136 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population for this study is African American cisgender women at least 18 years old residing in DHA (Durham Housing Authority) community housing. The vast majority of DHA residents are African American, so the investigators anticipate recruiting participants who are majority African American without explicitly excluding prospective participants on the basis of race.

Inclusion criteria

Women will be eligible to participate if they meet the following criteria:

  • 18 years of age or older
  • Identify as cisgender female (assigned female sex at birth and currently identify as female)
  • Currently reside in Durham Housing Authority (DHA) housing

Exclusion criteria

Exclusion Criteria:

Women will not be eligible to participate if they meet the following criteria:

  • Younger than 18 years of age
  • Do not Identify as cisgender female (assigned female sex at birth and currently identify as female)
  • Do not currently reside in Durham Housing Authority (DHA) housing
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
31 participants (actual)
Patient registry
No

Groups and cohorts

  • Focus Group

    There will be 4 focus groups of up to 12 women in each focus group.

    Behavioral: Gain framing plus demographically targeted photos · Behavioral: Loss framing plus demographically targeted photos · Behavioral: Gain framing plus not demographically targeted photos · Behavioral: Loss framing plus not demographically targeted photos

  • Survey Group

    There will be up to 200 women who complete the survey for this study.

    Behavioral: Gain framing plus demographically targeted photos · Behavioral: Loss framing plus demographically targeted photos · Behavioral: Gain framing plus not demographically targeted photos · Behavioral: Loss framing plus not demographically targeted photos

Interventions

  • BehavioralGain framing plus demographically targeted photos

    Gain framing: Participant feels PrEP puts her in control Participants (majority of whom will be African American) will be shown an image of women of multiple races.

  • BehavioralLoss framing plus demographically targeted photos

    Loss framing: Without PrEP, participant feels less in control Participants (majority of whom will be African American) will be shown an image of women of multiple races.

  • BehavioralGain framing plus not demographically targeted photos

    Gain framing: Participant feels PrEP puts her in control Participants (majority of whom will be African American) will be shown an image of an African American woman.

  • BehavioralLoss framing plus not demographically targeted photos

    Loss framing: Without PrEP, participant feels less in control Participants (majority of whom will be African American) will be shown an image of an African American woman.

06

What researchers measure

Primary outcomes

  1. Modified Jaspal, Lopes, and Maatouk Attitudes toward PrEP Scale (APS)

    A subset of the Attitudes toward PrEP Scale (APS) will be used to assess the association between message exposure and attitudes toward pre-exposure prophylaxis (PrEP). This sub-set scale will include nine items rated on a 5-point Likert scale (responses ranging from 1=Strongly Disagree to 5=Strongly Agree). The nine items are a sub-set of the original APS scale and will include four items comprising sub-scale 2, three items comprising sub-scale 3, and two items from sub-scale 1. A mean score will be calculated for each complete sub-scale (2 and 3) ranging from 1-5. Each of the two items from sub-scale 1 will be scored individually, ranging from 1-5. Higher scores indicate more positive attitudes toward PrEP.

    Time frame: Baseline

07

Study locations

1 site
  • University of North Carolina
    Chapel Hill, North Carolina 27514, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05087927
Lead sponsor
University of North Carolina, Chapel Hill
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Oct 21, 2021
Start date
Apr 18, 2023
Primary completion
Nov 28, 2023
Completion
Mar 10, 2024
Last update
Sep 20, 2024

Study contacts

Carol Golin, MD
principal investigator · UNC-Chapel Hill
Lauren Hill, PhD
principal investigator · UNC-Chapel Hill

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion